Ultragenyx Pharmaceutical INC 10-Q quarterly reports

Ultragenyx Pharmaceutical Inc. reported increased product sales and royalty revenue for the nine months ended September 30, 2025, alongside significant clinical advancements and a new $400 million royalty sale agreement.

Ultragenyx Pharmaceutical Inc. reported increased revenues and reduced net loss in Q2 2025, driven by product sales growth and royalty revenue, while advancing its gene therapy and biologic pipeline despite a regulatory setback for UX111.

Ultragenyx Pharmaceutical Inc. announces its Q1 2025 financial results, showcasing revenue growth driven by product sales and providing updates on its clinical development programs, particularly in gene therapy and biologics.

Ultragenyx Pharmaceutical Inc. announced a significant increase in revenue for the third quarter of 2024, driven by strong product sales and advancements in its clinical development programs.

Ultragenyx Pharmaceutical Inc. reported increased revenue driven by product sales in Q2 2024, while also highlighting progress in its gene therapy clinical programs.

Ultragenyx Pharmaceutical Inc. reported a net loss of $170.7 million for the first quarter of 2024, with total revenues reaching $108.8 million, primarily driven by increased product sales.